TY - JOUR T1 - Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz, and tenofovir JF - Antivir Ther Y1 - 2013 A1 - Bifano, M. A1 - Hwang, C. A1 - Oosterhuis, B. A1 - Hartstra, J. A1 - Grasela, D. A1 - Tiessen, R. A1 - Velinova-Donga, M. A1 - Kandoussi, H. A1 - Sevinsky, H. A1 - Bertz, R. KW - Adenine KW - administration & dosage KW - Adolescent KW - Adult KW - adverse effects KW - analogs & derivatives KW - antagonists & inhibitors KW - Anti-HIV Agents KW - Antiretroviral KW - Antiretrovirals KW - atazanavir KW - Benzoxazines KW - clinical trial KW - coinfection KW - Drug Interactions KW - drug therapy KW - efavirenz KW - Female KW - HCV KW - hepatitis KW - Hepatitis C KW - hepatitis C virus KW - HIV Infections KW - Humans KW - Imidazoles KW - Infection KW - Male KW - methods KW - Middle Aged KW - Oligopeptides KW - Organophosphonates KW - pharmacokinetic KW - pharmacokinetics KW - Proteins KW - Pyridines KW - Research KW - Research Support KW - ritonavir KW - tenofovir KW - treatment KW - Viral Nonstructural Proteins KW - Young Adult VL - 18 SP - 931-940 IS - 7 ER -